Alliance Foundation Trial (AFT) 46: CHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
- Citation:
- Meeting Instance:
- IASLC (WCLC) 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- AstraZenteca
- Grants:
- Corr. Author:
- Authors:
- Linda Martin Xiaofei Wang David Kozono James Urbanic Stephen Graziano Ray Osarogiagbon Reza Mehran John Wain Christine Bestvina Joe Gannon Steven Wolf Thomas Stinchcombe Jyoti Patel
- Networks:
- CA249, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-NC010, LAPS-TX035, NY141, VA009
- Study
- AFT-46
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Stage 3 (N2) lung cancer, perioperative immunotherapy, locally advanced NSCLC resection